CTKB (Cytek Biosciences) ROCE %: -18.21% (As of Mar. 2026)

What is Cytek Biosciences ROCE %?

Cytek Biosciences CTKB +0.11% 71 ROCE % is -18.21% as of Mar. 2026. GuruFocus rates CTKB with a GF Score™ of 71/100 and a GF Value™ of $5.82 (Modestly Undervalued). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cytek Biosciences's annualized ROCE % for the quarter that ended in Mar. 2026 was -18.21%.

Cytek Biosciences (NAS:CTKB) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cytek Biosciences ROCE % Related Terms

Cytek Biosciences ROCE % Historical Data

* Premium members only.

The historical data trend for Cytek Biosciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cytek Biosciences ROCE % Chart

Cytek Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

2.46

0.85

-3.00

-4.72

-7.20

Cytek Biosciences Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-10.37	-6.09	-6.93	-4.74	-18.21

71GF Score

Cytek Biosciences Inc CTKB

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Cytek Biosciences ROCE % Calculation

Cytek Biosciences's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-29.367	/	( ( (499.5 - 67.663)	+	(461.542 - 77.804) )	/ 2 )
	=	-29.367	/	( (431.837	+	383.738)	/ 2 )
	=	-29.367	/	407.7875
	=	-7.20 %

Cytek Biosciences's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-68.444	/	( ( (461.542 - 77.804)	+	(449.113 - 80.935) )	/ 2 )
	=	-68.444	/	( ( 383.738	+	368.178 )	/ 2 )
	=	-68.444	/	375.958
	=	-18.21 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -18.21% mean?

Cytek Biosciences (CTKB) has a ROCE % of -18.21% as of Mar. 2026.

Is Cytek Biosciences' ROCE % too high?

Cytek Biosciences' current ROCE % is -18.21%. Overall, Cytek Biosciences has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Cytek Biosciences' ROCE % compare to BBNX and TCMD?

Cytek Biosciences' ROCE % of -18.21% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Devices & Instruments company?

The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cytek Biosciences's current ROCE % is -18.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Cytek Biosciences stock overvalued right now?

Based on GuruFocus' analysis, Cytek Biosciences (CTKB) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.82, compared to a current price of $4.46 — trading 23.4% below its estimated fair value. The current ROCE % is -18.21%. Cytek Biosciences' overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Cytek Biosciences (CTKB), the current ROCE % is -18.21% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cytek Biosciences (CTKB) Overvalued in 2026?

Based on GuruFocus' analysis, Cytek Biosciences stock appears to be undervalued. The current stock price of $4.46 is trading 23.4% below its estimated GF Value™ of $5.82. GuruFocus considers Cytek Biosciences to be Modestly Undervalued.

Key valuation signals for CTKB:

ROCE %: -18.21%
GF Value™: $5.82 vs. price of $4.46 (23.4% below fair value)
GF Score™: 71/100 with 5 warning signs

No single metric tells the full story. See the CTKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cytek Biosciences Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies BBNX TCMD NPCE BVS CERS PACB SIBN CATX LAB KIDS ABT SYK MDT BSX EW XTER:SHL DXCM GEHC SZSE:300760 XAMS:PHIA

Other Exchanges 8EQ:Germany

Address 47215 Lakeview Boulevard, Fremont, CA, USA, 94538

Website https://www.cytekbio.com

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.

71GF Score

Get the complete analysis for CTKB

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.46

Price

$5.82

GF Value

View CTKB Analysis

See ROCE % data for all stocks →